Clinical trial
Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and…
NCT00395031 · Manhattan Psychiatric Center, Other · Completed
Key facts
| NCT number | NCT00395031 |
|---|---|
| Title | Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder |
| Official title | The Effects of Ziprasidone 320 mg on Glucose and Plasma Lipids in Patients With Diabetes Type II and Schizophrenia or Schizoaffective Disorder |
| Lead sponsor | Manhattan Psychiatric Center, Other |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia, Schizoaffective Disorder |
| Intervention type | Drug |
| Interventions | Ziprasidone |
| Enrollment | 57 |
| Start date | Sep 1, 2003 |
| Primary completion | Jan 1, 2010 |
| Completion | Jan 1, 2010 |
| First posted | Nov 2, 2006 |
| Last update posted | Jul 29, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: